Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
adalimumab
fibrosis
hidradenitis suppurativa
ultrasound
vascularization
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
08
10
2020
accepted:
21
12
2020
pubmed:
29
12
2020
medline:
25
5
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a debilitating skin disease presenting with nodules, abscesses, and fistulae preferentially in the main folds. Adalimumab is the only licensed biologic for moderate-to-severe HS. Ultrasound demonstrated good sensitivity to provide anatomic and functional information in HS; in particular assessing vascularization, related to inflammation, and fibrosis in HS lesions before and after adalimumab treatment with ultrasound and Color Doppler may integrate clinical evaluation with imaging. Patients with moderate-to-severe HS were enrolled in this observational prospective study. Clinical evaluation (according to Hurley classification and International Hidradenitis Suppurativa Severity Score System score) and ultrasound (according to US HS-PGA)/Color Doppler were performed at baseline and after 12 weeks of adalimumab. Ultrasound was used for assessing fibrosis and Color Doppler for vascularization. For each patient, the three most severe lesions among abscesses and fistulae were chosen for total 96 lesions. Thirty-two patients were included, 18 men (56%) and 14 women (44%) with mean age 41.2. Mean IHS4 was 22.4 at baseline and dropped to 14.7 at week 12. Based on US HS-PGA, 14 out of 32 patients fell down by one or more classes of severity. Interestingly, adalimumab led to overall decrease in vascularization, particularly in lesions with intense vascular flow, which were 78 (81.3%) at baseline and became only 25 (26.04%). Finally, marked increase in fibrosis was seen after adalimumab, notably in lesions without fibrosis, which were 81 (84.4%) at baseline and became 15 (15.6%). This study confirms the efficacy of adalimumab in HS and provides value for vascularization and fibrosis as important ultrasonographic tools integrating clinical scores.
Substances chimiques
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14706Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164.
Nazzaro G, Zerboni R, Passoni E, et al. High-frequency ultrasound in hidradenitis suppurativa as rationale for permanent hair laser removal. Skin Res Technol. 2019;25(4):587-588.
Wortsman X. Imaging of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):59-68.
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familiar benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH Jr, eds. Dermatologic Surgery: Principles and Practice. 2nd ed. New York, NY: Marcel Dekker; 1989:729-739.
Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401-1409.
Wortsman X, Moreno C, Soto R, Arellano J, Pezo C, Wortsman J. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg. 2013;39(12):1835-1842.
Wortsman X, Calderon P, Castro A. Seventy-MHz ultrasound detection of early signs linked to the severity, patterns of keratin fragmentation, and mechanisms of generation of collections and tunnels in hidradenitis suppurativa. J Ultrasound Med. 2020;39(5):845-857.
Nazzaro G, Passoni E, Guanziroli E, et al. Comparison of clinical and sonographic scores in a cohort of 140 patients with hidradenitis suppurativa from an Italian referral center: a retrospective observational study. Eur J Dermatol. 2018;28(6):845-847.
Nazzaro G, Passoni E, Muratori S, et al. Comparison of clinical and sonographic scores in hidradenitis suppurativa and proposal of a novel ultrasound scoring system. G Ital Dermatol Venereol. 2018. https://doi.org/10.23736/S0392-0488.18.06196-5.
Martorell A, Alfageme Roldán F, Vilarrasa Rull E, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.
Oranges T, Vitali S, Benincasa B, et al. Advanced evaluation of hidradenitis suppurativa with ultra-high frequency ultrasound: a promising tool for the diagnosis and monitoring of disease progression. Skin Res Technol. 2020;26(4):513-519.
Caposiena Caro RD, Solivetti FM, Bianchi L. Power Doppler ultrasound assessment of vascularization in hidradenitis suppurativa lesions. J Eur Acad Dermatol Venereol. 2018;32(8):1360-1367.
Nazzaro G, Passoni E, Calzari P, et al. Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions. Skin Res Technol. 2019;25(6):830-834.
Nazzaro G, Passoni E, Calzari P, Marzano AV. Ultrasonographic assessment of fibrosis in hidradenitis suppurativa fistulae helps in addressing treatment. Skin Res Technol. 2020;26(3):445-446.
Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434.
Marzano AV, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.18983.
Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176(6):1588-1598.
Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149(6):762-764.
Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80:60-9.e2.
Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III, randomized, placebo-controlled, PIONEER trials. Br J Dermatol. 2019;181:967-975.